These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

839 related articles for article (PubMed ID: 23860502)

  • 21. High FIB-4 index as an independent risk factor of prevalent chronic kidney disease in patients with nonalcoholic fatty liver disease.
    Xu HW; Hsu YC; Chang CH; Wei KL; Lin CL
    Hepatol Int; 2016 Mar; 10(2):340-6. PubMed ID: 26676626
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Natural History of Non-Alcoholic Fatty Liver Disease: A Study With Paired Liver Biopsies.
    Reddy YK; Marella HK; Jiang Y; Ganguli S; Snell P; Podila PSB; Maliakkal B; Satapathy SK
    J Clin Exp Hepatol; 2020; 10(3):245-254. PubMed ID: 32405181
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of simple scoring systems for a public health approach in the management of non-alcoholic fatty liver disease patients.
    Zain SM; Tan HL; Mohamed Z; Chan WK; Mahadeva S; Basu RC; Mohamed R
    JGH Open; 2020 Dec; 4(6):1155-1161. PubMed ID: 33319051
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Validation model of fibrosis-8 index score to predict significant fibrosis among patients with nonalcoholic fatty liver disease.
    Prasoppokakorn T; Chan WK; Wong VW; Pitisuttithum P; Mahadeva S; Nik Mustapha NR; Wong GL; Leung HH; Sripongpun P; Treeprasertsuk S
    World J Gastroenterol; 2022 Apr; 28(15):1563-1573. PubMed ID: 35582126
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of Liver Fibrosis Using Non-invasive Screening Tools in Individuals With Diabetes Mellitus and Metabolic Syndrome.
    Shaji N; Singhai A; Sarawagi R; Pakhare AP; Mishra VN; Joshi R
    Cureus; 2022 Feb; 14(2):e22682. PubMed ID: 35386158
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study.
    Bhala N; Angulo P; van der Poorten D; Lee E; Hui JM; Saracco G; Adams LA; Charatcharoenwitthaya P; Topping JH; Bugianesi E; Day CP; George J
    Hepatology; 2011 Oct; 54(4):1208-16. PubMed ID: 21688282
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of Six Noninvasive Methods for the Detection of Fibrosis in Chinese Patients with Obesity and Nonalcoholic Fatty Liver Disease.
    Chen G; Yang JC; Zhang GX; Cheng Z; Du X
    Obes Surg; 2022 Nov; 32(11):3619-3626. PubMed ID: 36070119
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stepwise combination of simple noninvasive fibrosis scoring systems increases diagnostic accuracy in nonalcoholic fatty liver disease.
    Demir M; Lang S; Nierhoff D; Drebber U; Hardt A; Wedemeyer I; Schulte S; Quasdorff M; Goeser T; Töx U; Steffen HM
    J Clin Gastroenterol; 2013 Sep; 47(8):719-26. PubMed ID: 23442837
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessment of the diagnostic accuracy of noninvasive scoring tools in predicting moderate-to-severe steatohepatitis via ultrasonography in asymptomatic healthy subjects admitted to family medicine outpatient clinics.
    Mert A
    Eur Rev Med Pharmacol Sci; 2023 Jul; 27(14):6530-6538. PubMed ID: 37522664
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic Value of Non-Invasive Fibrosis and Steatosis Tools, Hepatic Venous Pressure Gradient (HVPG) and Histology in Nonalcoholic Steatohepatitis.
    Sebastiani G; Alshaalan R; Wong P; Rubino M; Salman A; Metrakos P; Deschenes M; Ghali P
    PLoS One; 2015; 10(6):e0128774. PubMed ID: 26083565
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of liver fibrosis using non-invasive screening tools in individuals with diabetes mellitus and metabolic syndrome.
    Shaji N; Singhai A; Joshi R
    J Assoc Physicians India; 2022 Apr; 70(4):11-12. PubMed ID: 35443467
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD).
    Stepanova M; Rafiq N; Makhlouf H; Agrawal R; Kaur I; Younoszai Z; McCullough A; Goodman Z; Younossi ZM
    Dig Dis Sci; 2013 Oct; 58(10):3017-23. PubMed ID: 23775317
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Does the FT3-to-FT4 ratio easily predict the progression of NAFLD and NASH cirrhosis?
    Türker F; Oral A; Şahin T; Türker BÇ; Koçak E; Ataoğlu HE; Ahbab S
    J Int Med Res; 2021 Nov; 49(11):3000605211056841. PubMed ID: 34763561
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Steatosis severity affects the diagnostic performances of noninvasive fibrosis tests in nonalcoholic fatty liver disease.
    Joo SK; Kim W; Kim D; Kim JH; Oh S; Lee KL; Chang MS; Jung YJ; So YH; Lee MS; Bae JM; Kim BG
    Liver Int; 2018 Feb; 38(2):331-341. PubMed ID: 28796410
    [TBL] [Abstract][Full Text] [Related]  

  • 35. NAFLD fibrosis score: a prognostic predictor for mortality and liver complications among NAFLD patients.
    Treeprasertsuk S; Björnsson E; Enders F; Suwanwalaikorn S; Lindor KD
    World J Gastroenterol; 2013 Feb; 19(8):1219-29. PubMed ID: 23482703
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A simple scoring system using type IV collagen 7S and aspartate aminotransferase for diagnosing nonalcoholic steatohepatitis and related fibrosis.
    Okanoue T; Ebise H; Kai T; Mizuno M; Shima T; Ichihara J; Aoki M
    J Gastroenterol; 2018 Jan; 53(1):129-139. PubMed ID: 28589339
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development and Validation of Hepamet Fibrosis Scoring System-A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis.
    Ampuero J; Pais R; Aller R; Gallego-Durán R; Crespo J; García-Monzón C; Boursier J; Vilar E; Petta S; Zheng MH; Escudero D; Calleja JL; Aspichueta P; Diago M; Rosales JM; Caballería J; Gómez-Camarero J; Lo Iacono O; Benlloch S; Albillos A; Turnes J; Banales JM; Ratziu V; Romero-Gómez M;
    Clin Gastroenterol Hepatol; 2020 Jan; 18(1):216-225.e5. PubMed ID: 31195161
    [TBL] [Abstract][Full Text] [Related]  

  • 38. IMPACT OF TYPE 2 DIABETES ON NONALCOHOLIC STEATOHEPATITIS AND ADVANCED FIBROSIS IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE.
    Bian H; Zhu X; Xia M; Yan H; Chang X; Hu X; Pan B; Guo W; Li X; Gao X
    Endocr Pract; 2020 Apr; 26(4):444-453. PubMed ID: 31968197
    [No Abstract]   [Full Text] [Related]  

  • 39. Noninvasive parameters and hepatic fibrosis scores in children with nonalcoholic fatty liver disease.
    Yang HR; Kim HR; Kim MJ; Ko JS; Seo JK
    World J Gastroenterol; 2012 Apr; 18(13):1525-30. PubMed ID: 22509085
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Validation of the BARD scoring system in Polish patients with nonalcoholic fatty liver disease (NAFLD).
    Raszeja-Wyszomirska J; Szymanik B; Ławniczak M; Kajor M; Chwist A; Milkiewicz P; Hartleb M
    BMC Gastroenterol; 2010 Jun; 10():67. PubMed ID: 20584330
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.